Reviewer's report

Title: Stent thrombosis associated with drug eluting stents on addition of cilostazol to the standard dual antiplatelet therapy following Percutaneous Coronary Intervention: A systematic review and meta-analysis of published Randomized Controlled Trials

Version: 0 Date: 17 May 2018

Reviewer: Yubin Wu

Reviewer's report:

Author Huang aimed to systematically compare stent thrombosis and its different subtypes in patients who were treated with DAPT (aspirin and clopidogrel) versus TAPT (aspirin, clopidogrel and cilostazol).

This analysis was carried out for a short term duration time period of less than or equal to 6 months and a longer duration time period of greater or equal to 1 year.

The author concluded that no significant stent thrombosis was observed with the addition of cilostazol to DAPT following PCI.

This is a very interesting study with interesting results. Well written and well-presented. The conclusion is well-supported by the data, and data are adequate to reach a robust conclusion.

The idea concerning stent thrombosis and its different subtypes is new. Several previous meta-analyses have compared DAPT with TAPT but stent thrombosis especially its different subtypes (acute, subacute, late, definite and probable ST), and with different follow-up time periods were seldom systematically compared. Therefore, this analysis represents another novelty in the clinical literature of Interventional Cardiology.

The link between the title, the aim and the conclusion has well-been established. The abstract stands unique on itself summarizing the whole paper and it has well been structured.

Publication bias was adequately represented through funnel plots.

The paper is to the point, and very specific. I would like to congratulate the authors for such an interesting piece of information related specifically to drug eluting stents and the different types
of stent thrombosis; which well suits this Journal (since it is related to pharmacology and toxicology).

I would suggest some minor changes prior to publication of this article:

1. Please mention in the result section that, publication bias was represented through funnel plots because of the presence of a small volume of studies.
2. Please, add the name of any person who indirectly contributed to the data search or extraction or writing the final draft in the 'acknowledgement section' if they were not completely involved in the manuscript. For meta-analyses, there should be another person to check the data. The author might have ignored this, but names of persons who have contributed in any way to the manuscript has to be acknowledged.

I do not have any other comment. Thank you for presenting this work.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes

Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.
I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:
Acceptable
**Declaration of competing interests**

Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal